Oncology Institute, Inc.
TOIIWN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
TOIIW News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
marimastat
Lung Cancer
PNT2258
Lymphoma, Diffuse Large B-Cell
Momelotinib
Primary Myelofibrosis
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
marimastat | Phase 3 | Lung Cancer | - |
PNT2258 | Phase 2 | Lymphoma, Diffuse Large B-Cell | - |
Momelotinib | Phase 2 | Primary Myelofibrosis | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply